Kopran Ltd Stock Price Today (NSE: KOPRAN)
Fundamental Score
Kopran Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kopran Ltd share price today is ₹190.27, up +1.17% on NSE/BSE as of 3 August 2026. Kopran Ltd (KOPRAN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹983.98 (Cr). The 52-week high for KOPRAN share price is ₹219.00 and the 52-week low is ₹107.00. At a P/E ratio of 38.24x, KOPRAN is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.91% and a debt-to-equity ratio of 0.29.
Kopran Ltd Share Price Chart — NSE/BSE Historical Performance
Kopran Ltd share price chart: 1.24% return over the past month. 52-week high ₹219.00, 52-week low ₹107.00.
Kopran Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹188.22 | ₹194.60 | ₹182.15 | ₹190.27 | 61.77K (Cr) | |
| ₹190.40 | ₹195.55 | ₹187.00 | ₹191.03 | 62.69K (Cr) | |
| ₹191.60 | ₹194.99 | ₹185.00 | ₹188.07 | 88.92K (Cr) | |
| ₹197.20 | ₹201.60 | ₹189.38 | ₹191.64 | 1.09L (Cr) | |
| ₹201.21 | ₹202.50 | ₹197.00 | ₹199.34 | 1.45L (Cr) | |
| ₹201.90 | ₹204.00 | ₹197.99 | ₹201.21 | 51.20K (Cr) | |
| ₹198.50 | ₹199.90 | ₹195.00 | ₹198.74 | 72.31K (Cr) | |
| ₹206.80 | ₹207.00 | ₹203.10 | ₹204.01 | 1.16L (Cr) | |
| ₹202.00 | ₹210.00 | ₹202.00 | ₹203.13 | 1.33L (Cr) | |
| ₹205.98 | ₹207.40 | ₹200.00 | ₹203.63 | 1.01L (Cr) |
Kopran Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹188.22 | ₹194.60 | ₹182.15 | ₹190.27 | +1.09% | |
| ₹190.00 | ₹216.00 | ₹179.93 | ₹191.03 | +0.54% | |
| ₹197.40 | ₹213.50 | ₹175.00 | ₹189.31 | -4.10% | |
| ₹164.63 | ₹219.00 | ₹147.65 | ₹206.27 | +25.29% | |
| ₹111.50 | ₹166.60 | ₹110.24 | ₹164.63 | +47.65% | |
| ₹128.00 | ₹130.58 | ₹107.00 | ₹108.04 | -15.59% | |
| ₹125.00 | ₹146.83 | ₹119.81 | ₹131.83 | +5.46% | |
| ₹151.40 | ₹157.85 | ₹125.27 | ₹128.05 | -15.42% | |
| ₹133.50 | ₹159.89 | ₹127.52 | ₹150.43 | +12.68% | |
| ₹163.60 | ₹167.95 | ₹123.11 | ₹134.49 | -17.79% | |
| ₹174.36 | ₹184.00 | ₹164.61 | ₹165.37 | -5.16% | |
| ₹152.14 | ₹186.90 | ₹151.52 | ₹174.36 | +14.60% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kopran Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kopran Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KOPRAN across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (94.94%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.77%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (4.91%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.65%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (-17.86% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-16.05% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-132.88 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.51%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Kopran Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kopran Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kopran LtdKopran Ltd...Selected✓ KOPRAN • 524280 | 41.3/100 | ₹190.27₹190 | ₹983.98₹983.98 | 38.24Average 38.2 Average | 4.91%Poor 4.91% Poor | 6.65%Poor 6.65% Poor | 0.29Excellent 0.3 Excellent | -16.05%Poor -16.05% Poor | 6.74%Good 6.74% Good | 1.47% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Kopran Ltd PE Ratio History
Historical price-to-earnings ratio for KOPRAN — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹7.99 | ₹150.43 | 18.8x |
| FY 2024 | ₹10.55 | ₹211.78 | 20.1x |
| FY 2023 | ₹5.65 | ₹241.25 | 42.7x |
| FY 2022 | ₹13.77 | ₹150.85 | 11x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Kopran Ltd Dividend History
Annual cash dividends paid by KOPRAN — dividend yield 1.47%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.46 Cr |
| FY 2024 | ₹14.46 Cr |
| FY 2023 | ₹14.46 Cr |
| FY 2022 | ₹6.49 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Kopran Ltd Quarterly Performance
Latest quarterly metrics for KOPRAN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.77%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
94.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-16.05%
Compounded annual net profit growth over 5 years
Kopran Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KOPRAN — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kopran Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kopran Ltd (KOPRAN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Kopran Ltd
About KOPRAN (Kopran Ltd)
Kopran Ltd is a pharmaceutical entity forging a path in the global landscape, distinguished by its comprehensive approach to healthcare solutions. The company deftly navigates the ...spectrum from foundational active pharmaceutical ingredients (APIs) to the creation of diverse finished dosage forms. With a commitment to accessibility, Kopran addresses a wide range of medical needs, crafting formulations that include both branded innovations and widely accessible generic alternatives. This dedication to providing diverse options allows them to cater to varied patient populations across both India and the global stage, reinforcing their commitment to widespread health accessibility. The company's manufacturing prowess is evident in its extensive product portfolio, encompassing an array of dosage forms designed to meet diverse patient requirements. From easily administered tablets and capsules to convenient syrups and suspensions, and even advanced injectables and specialized dry powder formulations, Kopran demonstrates a versatility that sets it apart. This breadth of capabilities allows them to deliver therapeutic solutions that are tailored to specific conditions and patient preferences, ensuring optimal treatment outcomes. The meticulous attention to detail in each stage of production underscores their commitment to quality and patient well-being. Kopran's therapeutic focus encompasses a broad spectrum of prevalent health challenges. Their product offerings include critical medications across several important categories, such as macrolides for managing infections, potent antibacterials to combat resistant strains, and anticonvulsants for neurological care. Additionally, they provide essential anti-hypertensive drugs for cardiovascular health, and effective anti-helminth medications for parasite control. This strategic targeting of key therapeutic areas demonstrates Kopran's dedication to addressing pressing global health needs, contributing to the overall improvement of patient care and well-being across diverse communities.
Company Details
Key Leadership
Corporate Events
KOPRAN Share Price: Frequently Asked Questions
What is the current share price of Kopran Ltd?
Kopran Ltd (KOPRAN) trades at ₹190.27 on NSE and BSE. Market cap ₹983.98 (Cr). Educational data only.
What is the P/E ratio of Kopran Ltd?
Kopran Ltd has a P/E of 38.24x vs industry average 34.89x.
What is the Bull Run score for Kopran Ltd?
Kopran Ltd has a Bull Run score of 41.3/100 based on 25+ financial parameters.
Does Kopran Ltd pay dividends?
Kopran Ltd has a dividend yield of 1.47%. Past dividends don't guarantee future payments.
What is the ROE of Kopran Ltd?
Kopran Ltd has ROE of 4.91%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kopran Ltd?
Kopran Ltd has debt-to-equity of 0.29.
Is Kopran Ltd a good investment?
Bull Run gives Kopran Ltd a score of 41.3/100. This is not investment advice — consult a SEBI-registered advisor.